Specific detection of anabasine, nicotine, and nicotine metabolites in urine by liquid chromatography-tandem mass spectrometry

American Journal of Clinical Pathology

Volumn 126, Issue 6, 2006, Pages 880-887

  Hoofnagle, Andrew N ^a   Laha, Thomas J ^a   Rainey, Petrie M ^a   Sadrzadeh, Sayed M H ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Anabasine; Cotinine; Direct injection; Interference; Liquid chromatography mass spectrometry; Nicotine; Nornicotine; Trans 3 hydroxycotinine; Urine

Indexed keywords

ANABASINE; NICOTINE;

ANALYTIC METHOD; ARTICLE; CIGARETTE SMOKING; HEALTH INSURANCE; HUMAN; LIQUID CHROMATOGRAPHY; METABOLITE; ORGAN TRANSPLANTATION; PASSIVE SMOKING; PRIORITY JOURNAL; SMOKING CESSATION; SURGICAL PATIENT; TANDEM MASS SPECTROMETRY; TOBACCO; URINE LEVEL;

EID: 33845427483     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/LQ8U3UL956ET324X     Document Type: Article

References (26)

1. Doolittle DJ, Winegar R, Lee CK, et al. The genotoxic potential of nicotine and its major metabolites. Mutat Res. 1995;344:95-102.
2. Bergen AW, Caporaso N. Cigarette smoking. J Natl Cancer Int. 1999;91:1365-1375.
3. Yildiz D. Nicotine, its metabolism and an overview of its biological effects. Toxicon. 2004;43:619-632.
4. Centers for Disease Control and Prevention. Annual smoking attributable mortality, years of potential life lost, and economic costs: United States, 1995-1999. MMWR Morb Mortal Wkly Rep. 2002;51:300-303.
5. Lackmann GM, Salzberger U, Tollner U, et al. Metabolites of a tobacco-specific carcinogen in urine from newborns. J Natl Cancer Inst. 1999;91:459-465.
6. Wing KJ, Fisher CG, O'Connell JX, et al. Stopping nicotine exposure before surgery: the effect on spinal fusion in a rabbit model. Spine. 2000;25:30-34.
7. Ehlers SL, Rodrigue JR, Widows MR, et al. Tobacco use before and after liver transplantation: a single center survey and implications for clinical practice and research. Liver Transpl. 2004;10:412-417.
8. Kaufman T, Eichenlaub EH, Levin M, et al. Tobacco smoking: impairment of experimental flap survival. Ann Plast Surg. 1984;13:468-472.
9. Henningfield JE, Fant RV, Buchhalter AR, et al. Pharmacotherapy for nicotine dependence. CA Cancer J Clin. 2005;55:281-299.
10. Jacob P, Yu L, Shulgin AT, et al. Minor tobacco alkaloids as biomarkers for tobacco use: comparison of users of cigarettes, smokeless tobacco, cigars, and pipes. Am J Public Health. 1999;89:731-736.
11. Dhar P. Measuring tobacco smoke exposure: quantifying nicotine/cotinine concentration in biological samples by colorimetry, chromatography and immunoassay methods. J Pharm Biomed Anal. 2004;35:155-168.
12. Gariti P, Rosenthal DI, Lindell K, et al. Validating a dipstick method for detecting recent smoking. Cancer Epidemiol Biomarkers Prev. 2002;11:1123-1125.
13. Ziegler UE, Kauczok J, Dietz UA, et al. Clinical correlation between the consumption of nicotine and cotinine concentrations in urine and serum by competitive enzyme-linked immunosorbent assay. Pharmacology. 2004;72:254-259.
14. Ghosheh OA, Browne D, Rogers T, et al. A simple high performance liquid chromatographic method for the quantification of total cotinine, total 3′-hydroxycotinine and caffeine in the plasma of smokers. J Pharm Biomed Anal. 2000;23:543-549.
15. Jung BH, Chung BC, Chung SJ, et al. Simultaneous GC-MS determination of nicotine and cotinine in plasma for the pharmacokinetic characterization of nicotine in rats. J Pharm Biomed Anal. 1999;20:195-202.
16. Xu X, Iba MM, Weisel CP. Simultaneous and sensitive measurement of anabasine, nicotine, and nicotine metabolites in human urine by liquid chromatography-tandem mass spectrometry. Clin Chem. 2004;50:2323-2330.
17. Tuomi T, Johnsson T, Reijula K. Analysis of nicotine, 3-hydroxycotinine, cotinine, and caffeine in urine of passive-smokers by HPLC-tandem mass spectrometry. Clin Chem. 1999;45:2164-2172.
18. Moyer TP, Charlson JR, Enger RJ, et al. Simultaneous analysis of nicotine, nicotine metabolites, and tobacco alkaloids in serum or urine by tandem mass spectrometry, with clinically relevant metabolic profiles. Clin Chem. 2002;48:1460-1471.
19. Meger M, Meger-Kossien I, Schuler-Metz A, et al. Simultaneous determination of nicotine and eight nicotine metabolites in urine of smokers using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;778:251-261.
20. Hukkanen J, Jacob P, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005;57:79-115.
21. Cognard E, Staub C. Determination of nicotine and its major metabolite cotinine in plasma or serum by gas chromatography-mass spectrometry using ion-trap detection. Clin Chem Lab Med. 2003;41:1599-1607.
22. Bernert JT, Turner WE, Pirkle JL, et al. Development and validation of sensitive method for determination of serum cotinine in smokers and nonsmokers by liquid chromatography atmospheric pressure ionization tandem mass spectrometry. Clin Chem. 1997;43:2281-2291.
23. Bentley MC, Abrar M, Kelk M, et al. Validation of an assay for the determination of cotinine and 3-hydroxycotinine in human saliva using automated solid-phase extraction and liquid chromatography with tandem mass spectrometric detection. J Chromatogr B. 1999;723:185-194.
24. Jacob P, Hatsukami D, Severson H, et al. Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev. 2002;11:1668-1673.
25. Nordgren HK, Beck O. Multicomponent screening for drugs of abuse: direct analysis of urine by LC-MS-MS. Ther Drug Monit. 2004;26:90-97.
26. Nordgren HK, Holmgren P, Liljeberg P, et al. Application of direct urine LC-MS-MS analysis for screening of novel substances in drug abusers. J Anal Toxicol. 2005;29:234-239.